Jpmorgan Chase & CO Larimar Therapeutics, Inc. Put Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding LRMR
# of Institutions
128Shares Held
67.3MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$134 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$38.3 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$35.2 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$26.9 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$26.4 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $274M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...